[go: up one dir, main page]

CA3163139A1 - Compositions et methodes pour le traitement du cancer - Google Patents

Compositions et methodes pour le traitement du cancer

Info

Publication number
CA3163139A1
CA3163139A1 CA3163139A CA3163139A CA3163139A1 CA 3163139 A1 CA3163139 A1 CA 3163139A1 CA 3163139 A CA3163139 A CA 3163139A CA 3163139 A CA3163139 A CA 3163139A CA 3163139 A1 CA3163139 A1 CA 3163139A1
Authority
CA
Canada
Prior art keywords
seq
lrp2
dsrna
rnai agent
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3163139A
Other languages
English (en)
Inventor
Vivienne I. Rebel
David J. ELZI
William E. Bauta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioaffinity Technologies Inc
Original Assignee
Bioaffinity Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioaffinity Technologies Inc filed Critical Bioaffinity Technologies Inc
Publication of CA3163139A1 publication Critical patent/CA3163139A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un agent d'interférence ARN double brin (ARNi) comprenant au moins un élément parmi (i) un premier acide ribonucléique double brin (ARNdb) destiné à inhiber l'expression d'un gène CD320, le premier ARNdb comprenant un brin sens et un brin antisens formant un duplex, (ii) un second ARNdb destiné à inhiber l'expression d'un gène LRP2, le second ARNdb comprenant un brin sens et un brin antisens formant un duplex, ou (iii) un cocktail de (i) et (ii), le brin sens du premier ARNdb étant au moins sensiblement complémentaire du brin antisens du premier ARNdb et le brin sens du second ARNdb étant au moins sensiblement complémentaire du brin antisens du second ARNdb et l'utilisation de l'agent ARNi en tant que composition pharmaceutique pour le traitement du cancer chez des sujets ayant besoin d'un traitement.
CA3163139A 2018-12-27 2019-12-23 Compositions et methodes pour le traitement du cancer Pending CA3163139A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785592P 2018-12-27 2018-12-27
US62/785,592 2018-12-27
PCT/US2019/068423 WO2020139866A2 (fr) 2018-12-27 2019-12-23 Compositions et méthodes pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3163139A1 true CA3163139A1 (fr) 2020-07-02

Family

ID=71129313

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3163139A Pending CA3163139A1 (fr) 2018-12-27 2019-12-23 Compositions et methodes pour le traitement du cancer

Country Status (4)

Country Link
EP (1) EP3902917A4 (fr)
CN (1) CN113508175B (fr)
CA (1) CA3163139A1 (fr)
WO (1) WO2020139866A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
CA3174172A1 (fr) * 2021-06-28 2023-07-26 Bioaffinity Technologies, Inc. Compositions et methodes de traitement du cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US20030004311A1 (en) * 1997-06-18 2003-01-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
WO2001053455A2 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides associes
US20080050393A1 (en) * 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
JP4865377B2 (ja) * 2006-03-28 2012-02-01 国立大学法人 新潟大学 ヒトメガリンの測定方法
CA2648718A1 (fr) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Polypeptides du recepteur de la transcobalamine, acides nucleiques et modulateurs associes, procedes d'utilisation associes destines a moduler la croissance cellulaire et a traiter le cancer et la deficience en cobalamine
US9044461B2 (en) * 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
JP2009538603A (ja) * 2006-06-02 2009-11-12 ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド 微生物の検出および分析に使用するための微生物改変核酸
US8440629B2 (en) * 2007-03-21 2013-05-14 Raptor Pharmaceuticals Inc. Cyclic receptor-associated protein (RAP) peptides
US10113201B2 (en) * 2013-04-05 2018-10-30 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof
DK3325662T3 (da) * 2015-07-17 2023-11-27 Pacylex Pharmaceuticals Inc Epigenetisk inaktivering af nmt2
WO2017223273A1 (fr) * 2016-06-22 2017-12-28 President And Fellows Of Harvard College Inhibition de cellules lymphoïdes innées de groupe 3 du côlon

Also Published As

Publication number Publication date
CN113508175A (zh) 2021-10-15
EP3902917A2 (fr) 2021-11-03
CN113508175B (zh) 2025-08-19
EP3902917A4 (fr) 2022-11-30
WO2020139866A3 (fr) 2020-10-15
WO2020139866A2 (fr) 2020-07-02

Similar Documents

Publication Publication Date Title
JP7504482B2 (ja) ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
JP7357002B2 (ja) 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド
US20220170025A1 (en) Compositions and methods for inhibiting gene expression in the central nervous system
EP3394259B1 (fr) Compositions et méthodes pour diminuer l'expression de tau
CN113811311A (zh) 用于组织特异性apoe调节的寡核苷酸
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
BR112017018383B1 (pt) Compostos anti-sentido que induzem a inclusão de éxon2, composições farmacêuticas que compreendem ditos compostos e usos dos mesmos para tratar doença de armazenamento de glicogênio tipo ii
JP2011516094A (ja) 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
CN114375194A (zh) 血管生成素样7（angptl7）相关疾病的治疗
US20230357774A1 (en) Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
TW202345866A (zh) 用於抑制補體因子ｂ的組成物及方法
CN105555279B (zh) 用于治疗脓毒症的MicroRNA抑制
CA3163139A1 (fr) Compositions et methodes pour le traitement du cancer
US12305171B2 (en) Compositions and methods for treating cancer
ES2753355T3 (es) ARN de interferencia pequeño (ARNip) para la terapia de osteopetrosis autosómica dominante de tipo 2 (ADO2) provocada por mutación del gen CLCN7 (ADO2 dependiente de CLCN7)
CA3174172A1 (fr) Compositions et methodes de traitement du cancer
US20250243486A1 (en) Compositions and methods for inhibiting stag1 expression and uses thereof
EP4446414A1 (fr) Complexe d'oligonucléotide antisens
HK40062991A (en) Compositions and methods for treating cancer
Wang Poly (ethylene) Glycol-Based Bottlebrush Polymers as Nanocarriers for Oligonucleotide Therapeutics: Design, Synthesis, and Applications
WO2023112931A1 (fr) Oligonucléotide antisens ciblant l'arnm ou le pré-arnm atn1
WO2023154729A2 (fr) Compositions et procédés de régénération de tissu cardiaque
HK40068617A (en) Treatment of angiopoietin like 7 (angptl7) related diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923

EEER Examination request

Effective date: 20220923